. Author manuscript; available in PMC: 2021 Jun 11.

Published in final edited form as: Eur J Nucl Med Mol Imaging. 2016 Mar 21;43(10):1784–1791. doi: 10.1007/s00259-016-3357-x

Table 2.

Numbers of lesions identified on ⁶⁸Ga-DOTATATE, ¹⁸F-FDG, ¹⁸F-FDOPA and ¹⁸F-FDA PET/CT, and CT/MRI compared to lesions identified by the imaging comparator

Lesion location	⁶⁸Ga-DOTATATE PET/CT	¹⁸F-FDG PET/CT	¹⁸F-FDOPA PET/CT^a	¹⁸F-FDA PET/CT^a	CT/MRI
All compartments	450/461	226/461	181/242	160/206	376/461
Mediastinum	46/46	26/46	17/24	21/21	27/46
Lungs	89/94	52/94	52/53	26/38	89/94
Abdomen	74/74	42/74	30/41	35/38	57/74
Liver	42/48	6/48	11/13	9/13	45/48
Bone	199/199	100/199	71/111	69/96	158/199

Not all patients underwent PET/CT scans with these radiopharmaceuticals